ClinicalTrials.gg
Active, not recruitingNCT05677360HPV MISTICSUpdated Oct 29, 2026

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

An interventional study of HPV MISTICS -Provider Level and HPV MISTICS - Parent Level in Human Papilloma Virus (HPV) Vaccine, sponsored by H. Lee Moffitt Cancer Center and Research Institute. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute · Not applicable, Interventional, and Prevention

How we know

Updated Oct 29, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies in Papillomavirus Infections with a site in United States — 32 open to participants now, 60 under way, 5 of them phase 3. Papillomavirus Infections · United States.

Enrollment
63rd of 132
148 · median 128
Started
2023
with 13 others
No phase
53 of 166
14 open now
Primary completion
2026-12
later than 18 of 59 live
Registered
125th of 166
by date

Among the 166 studies in Papillomavirus Infections with a site in United States, this one is the 63rd largest by enrollment of the 132 interventional ones that give a count, is one of 14 that started in 2023, is one of 53 with no phase, reaches primary completion later than 18 of the 59 other live ones, and was the 125th registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

32 of the 166 studies in Papillomavirus Infections with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Papillomavirus Infections with a site in United States, or all of them as a file.
02

Study summary

This intervention study will use parent-, provider-, and health center-level strategies to promote HPV vaccination among 11-17 year olds receiving care in 8 community health centers in Florida, will explore factors related to the intervention effect, and will explore implementation outcomes of the intervention.

Read the detailed description

The goals of this multi-level intervention study are to: 1) test whether HPV MISTICS intervention increases human papillomavirus (HPV) vaccine initiation and completion rates among 11-17-year-old adolescents in 8 Health Choice Network-affiliated community health centers in Florida. 2) Explore other factors related to the intervention effect. 3) Explore implementation outcomes (i.e., reach, adoption, implementation, maintenance, and sustainability) and identify implementation barriers and facilitators with a focus on equity. The study will use parent-, provider-, and health center-level strategies to promote HPV vaccination.

03

Conditions studied

  • Human Papilloma Virus (HPV) Vaccine

Keywords

  • Human Papillomavirus
  • Vaccination
  • Multi-level intervention
  • Community Health Centers
  • Behavioral
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • For Staff:
  • 18 years of age or older
  • Working within the participating Federally Qualified Health Center system
  • Able to read, write and speak English
  • For Providers:
  • 18 years of age or older
  • Working within the participating Federally Qualified Health Center system
  • Interacting with parents of adolescents ages 11-17
  • Able to read, write and speak English
  • For parents:
  • Parent of 11-17 year old child that has received care within the prior two months at one of the participating Federally Qualified Health Centers
  • Whose child has not initiated or completed the HPV vaccine series at the time of their last visit
  • Able to read, write and speak English or Spanish, or Haitian Creole
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Wave 1: Initial Community Health Centers

    Initial group of community health centers to receive intervention

    Behavioral: HPV MISTICS -Provider Level · Behavioral: HPV MISTICS - Parent Level · Behavioral: HPV MISTICS- HPV Vaccine Champion Level

  • Experimental
    Wave 2: Second Community Health Centers

    Second group of community health centers to receive intervention

    Behavioral: HPV MISTICS -Provider Level · Behavioral: HPV MISTICS - Parent Level · Behavioral: HPV MISTICS- HPV Vaccine Champion Level

Interventions

  • BehavioralHPV MISTICS -Provider Level

    The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.

  • BehavioralHPV MISTICS - Parent Level

    The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.

  • BehavioralHPV MISTICS- HPV Vaccine Champion Level

    The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses

06

What researchers measure

Primary outcomes

  1. Effectiveness: HPV Vaccine series initiation rates

    HPV vaccine series initiation (1st dose) rates among adolescents ages 11-17 will be determined on a monthly basis as well as annually. Providers' vaccination rate data for their patient panel (using Florida SHOTS - a free, statewide centralized online immunization information system) will be compared to the National Immunization Survey-Teen (NIS-TEEN) data for the state of Florida.

    Time frame: at 5 years

  2. Effectiveness: HPV Vaccine series completion rates

    HPV vaccine series completion (2nd and 3rd dose) rates among adolescents ages 11-17 will be determined on a monthly basis as well as annually. Providers' vaccination rate data for their patient panel (using Florida SHOTS - a free, statewide centralized online immunization information system) will be compared to the National Immunization Survey-Teen (NIS-TEEN) data for the state of Florida.

    Time frame: at 5 years

Secondary outcomes

  1. Implementation outcome: Reach

    The intervention's implementation will be evaluated for reach - proportion of eligible patients that receive the intervention.

    Time frame: at 5 years

  2. Implementation outcome: Reach demographics

    The intervention's implementation will be evaluated for reach - demographics of patients reached.

    Time frame: at 5 years

  3. Proportion of Healthcare providers who participate in the intervention

    The proportion of health care providers who participate in the intervention, measured by contact log data.

    Time frame: at 5 years

  4. Proportion of Healthcare Providers, Rural vs Urban

    The proportion of health care providers in rural vs urban Federally Qualified Health Centers in network that participate.

    Time frame: at 5 years

  5. Proportion of Health Care providers who complete training

    The proportion of participating health care providers and staff who complete training per site will be measured using the training attendance log

    Time frame: at 5 years

  6. Intervention Sustainability: Health care Providers

    Long term intervention effects and use over time will be determined semi-structured interviews of providers

    Time frame: at 5 years

  7. Intervention Sustainability: Healthcare staff

    Long term intervention effects and use over time will be determined semi-structured interviews of health care staff.

    Time frame: at 5 years

07

Study locations

1 site
08

References and documents

Publications

  • Christy SM, Patel L, Arevalo M, Fuzzell L, Whitmer A, Turner K, Gore LR, Chung-Bridges K, Parras D, Endemano EY, Brownstein NC, Vadaparampil ST. HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS): Study protocol for a hybrid 1 stepped-wedge cluster randomized trial. Contemp Clin Trials. 2024 Jul;142:107576. doi: 10.1016/j.cct.2024.107576. Epub 2024 May 17. PubMed 38763306 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

Of 110 non-industry interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 47 months is above that.

Counting every sponsor, half of 119 studies reached it within 26 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2022
First posted
Jan 10, 2023
StartActual
Jan 9, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Active, not recruiting Reason for stopping removed
changed Oct 29, 2026
Enrollment
564 (estimated)→148 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Suspended→Active, not recruiting
    Why stopped Reason for stopping removed
    Enrollment 564 (estimated)→148 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05677360
Collaborators
Florida Department of Health, Health Choice Network
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Jan 9, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Susan T Vadaparampil, PhD, MPH
principal investigator · Moffitt Cancer Center
Shannon Christy, PhD
principal investigator · Moffitt Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion